NasdaqGM:VERABiotechs
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy
Earnings picture during a key regulatory phase
Vera Therapeutics (VERA) reported a first quarter net loss of US$121.03 million, compared with US$51.69 million a year earlier, as it pushes atacicept toward potential approval for IgA nephropathy.
Basic and diluted loss per share from continuing operations came in at US$1.69, versus US$0.81 in the prior year period. This provides a snapshot of how much capital the company is currently investing ahead of the July 7, 2026 FDA decision.
See our...